Physician profile
Anmar Mansour
NPI 1881617884
$1,799.21
in general payments reported to CMS, 2019-2025
14 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $52.75 · 2021: $285 · 2022: $121 · 2023: $158 · 2024: $637 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $478.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $246.32 | 2024 | Arexvy |
| Novo Nordisk INC | $229.01 | 2021-2023 | Wegovy |
| Daiichi Sankyo INC. | $214.81 | 2019-2021 | |
| Allergan, INC. | $135.42 | 2019 | |
| Merck Sharp & Dohme LLC | $121.26 | 2022 | |
| Lilly USA, LLC | $118.81 | 2024 | Mounjaro |
| Avion Pharmaceuticals | $75.83 | 2020-2021 | |
| Abbvie INC. | $43.70 | 2021-2023 | |
| Shield Therapeutics INC | $41.01 | 2025 | |
| Hologic Sales and Service, LLC | $37.43 | 2019 | |
| Astellas Pharma US INC | $28.71 | 2024 | Veozah |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Pfizer INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anmar Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.